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Abstract 
[D-Lys3]-Growth Hormone Releasing Peptide-6 (DLS) is widely utilized in vivo and in vitro as a 
selective ghrelin receptor (GHS-R) antagonist. Unexpectedly, we identified that DLS also has 
the ability to block CXCL12 binding and activity through CXCR4 on T cells and peripheral 
blood mononuclear cells (PBMCs). Moreover, as CXCR4 has been shown to act as a major 
co-receptor for HIV-1 entry into CD4 positive host cells, we have also found that DLS par-
tially blocks CXCR4-mediated HIV-1 entry and propagation in activated human PBMCs. 
These data demonstrate that DLS is not the specific and selective antagonist as thought for 
GHS-R1a and appears to have additional effects on the CXCR4 chemokine receptor. Our 
findings also suggest that structural analogues that mimic DLS binding properties may also 
have properties of blocking HIV infectivity, CXCR4 dependent cancer cell migration and 
attenuating chemokine-mediated immune cell trafficking in inflammatory disorders. 
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Introduction 
Chemokines are small peptides that are known 
to  exert  potent  regulatory  effects  on  migration  and 
activation of various immune and non hematopoietic 
cells  via  ligation  to  their  seven  transmembrane 
G-protein coupled receptors (GPCRs) [1, 2]. The CXC 
chemokine, CXCL12, also known as SDF-1is highly 
expressed in bone marrow stromal cells and potently 
stimulates the migration of T cells and monocytes via 
interactions with its cell surface receptor, CXCR4 re-
ceptor [3]. CXCR4 is widely expressed on hematopoi-
etic  stem  cells,  cells  of  the  central  nervous  system, 
monocytes and T and B lymphocytes [4]. Interesting-
ly, the chemokine receptors CXCR4 and CCR5 have 
attracted substantial interest because they form por-
tals of cellular entry for the human immunodeficiency 
viruses (HIV-1 and HIV-2) and related simian or fe-
line  retroviruses[5].  While  all  the  HIV-1  strains  re-
quire CD4 to enter and infect cells, several laboratory 
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and clinical HIV-1 variants utilize the chemokine re-
ceptors  CXCR4  (for  T-tropic/X4  strain  or  syncyti-
um-inducing viruses), CCR5 (for M-tropic/R5 strain 
or non-syncytium-inducing viruses) and/or both re-
ceptors (for dual tropic R5X4 strains) for binding and 
entry. Several HIV-1 chemokine co-receptor antago-
nists  have  been  recently  discovered  and  are  being 
utilized  in  human  clinical  trials  [5].  In  addition  to 
pathogenesis  of  HIV,  CXCR4  and  CCR5  have  been 
implicated in motility, invasion and  metastasis of a 
wide variety of cancer cell types [2, 6]. Given the in-
volvement of CXCR4 and CCR5 in HIV, cancers, stem 
cell  mobilization  and  inflammation,  these  receptors 
have  emerged  as  potential  targets  for  therapeutic 
manipulation and intervention [5]. 
 Growth  hormone  secretagogue  receptor 
(GHS-R) belongs to the seven transmembrane GPCR 
family  and  serves  as  an  endogenous  ligand  for  the 
predominantly stomach-derived hormone ghrelin [7, 
8]. Growth hormone releasing peptide-6 (GHRP-6) is 
one of the earliest synthetic peptidyl GHS-R agonist 
utilized to study the functions of GHS-R prior to the 
discovery of the endogenous ligand ghrelin [9]. Mod-
ification  of  GHRP-6  (H-His-D-Trp-Ala-Trp-D- 
Phe-Lys-NH2) from alanine to D-lysine resulted in a 
GHS-R  antagonist,  D-[Lys3]GHRP-6 
(H-His-D-Trp-D-Lys-Trp-D-Phe-Lys-NH2).  Current-
ly, the D-[Lys3]GHRP-6 (DLS) is utilized in vitro and 
in vivo studies as a selective GHS-R antagonist [8, 9] 
(Figure 1).  
 
 
Figure 1. Chemical structure of D-Lys3-GHRP-6. 
 
However,  no  studies  have  yet  addressed  the 
specificity  and  efficacy  of  this  compound  on 
ghrelin-specific effects using human T lymphocytes, T 
cell  lines,  PBMCs  or  other  immune  cell  subsets. 
However,  while  utilizing  DLS  as  a  control  in  some 
chemokine  binding  and  functional  experiments,  we 
found that DLS partially inhibited CXCR4 functions 
and signaling. Given the potent effects of ghrelin on 
human  T  cell  and  monocyte  responses  [10-13],  we 
have  subsequently  evaluated  the  specificity  of  DLS 
and its potential interactions with GHS-R1a as well as 
other immunologically relevant GPCRs of chemokine 
family. Here, we present evidence that DLS serves as 
a partial antagonist for the CXCR4 receptor and has 
an impact on receptor signaling, function and its abil-
ity to serve as an HIV-1 co-receptor.  
Materials and Methods 
Cell culture and Cell lines. 
GHOST-CXCR4  [14],  H9  and  Molt-4  cell  lines, 
the  CXCR4  receptor  antagonist  bicyclam  JM-2987 
(hydrobromide salt of AMD-3100) [15] and HIV1-IIIB 
[16] were obtained from the AIDS Research and Ref-
erence  Reagent  Program,  Division  of  AIDS,  NIAID, 
NIH  (GHOST-CXCR4  from  Dr.  Vineet  N. 
KewalRamani and Dr. Dan R. Littman, H9 from Dr. 
Robert  Gallo,  Molt-4  from  Dr.  Ronald  Desrosiers, 
HIV-IIIB from Dr. Robert Gallo). Leukapheresis packs 
were prepared from healthy male volunteers under an 
IRB-approved apheresis protocol between the age of 
18 and 45 and the packs were subsequently processed 
for the isolation of PBMCs and T cells. PBMCs were 
obtained  by  Ficoll-Hypaque  density  centrifugation 
and T cells were obtained using R&D T-cell Enrich-
ment columns (R&D Systems, Minneapolis, MN). 
Intracellular calcium mobilization.  
Measurement of intracellular calcium release in 
response  to  CXCL12  was  performed  as  described 
previously and as described in the figure legends [17]. 
T cells were incubated in PBS containing 5 mM Fura-2 
acetoxymethyl ester (Molecular Probes) for 30 minutes 
at  room  temperature.  The  cells  were  subsequently 
washed and then resuspended at 1 x 106/ml in PBS. A 
total of 1.5 ml of the cell suspension was placed in a 
continuously stirring cuvette at room temperature in 
an  LS50B  spectrophotometer  (Perkin-Elmer,  Welles-
ley, Massachusetts, USA). Labeled T cells were treated 
with  CXCL12  (100ng/ml)  with  or  without  DLS 
(Phoenix  pharmaceuticals,  Burlingame,  California, 
USA)  at  various  concentrations.  Fluorescence  was 
monitored at λex1 = 340 nm, λex2 = 380 nm, and λem = 
510 nm. The data are presented as the relative ratio of 
fluorescence excited at 340 and 380 nm. 
Fluorokine ligand binding assays. 
Fluorokine binding assay was performed as de-
scribed  previously  and  in  the  Figure  legends  [18]. 
Briefly, biotinylated CXCL12 (Fluorokine; R&D Sys-Int. J. Biol. Sci. 2012, 8 
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tems) ligand binding was performed according to the 
R&D Systems kit protocol, with slight modifications. 
GHOST-CXCR4 cells were resuspended in PBS at 4 x 
106cells/ml. 25l of cells were treated with 1, 4 or 16 
g of DLS at 37°C for 30 min, then mixed with 20 µl of 
2.5 µg/ml biotinylated CXCL12 and incubated at 4°C 
for 1 h. 20l fluorescein-conjugated avidin (10 µg/ml) 
was added to the cells and incubated for an additional 
30  min  at  4°C.  After  incubation,  cells were  washed 
with 1x RDF-1 buffer (R&D Systems) and then fixed 
with 2% paraformaldehyde in PBS before being ana-
lyzed on a FACScan (BD Biosciences) flow cytometer.  
Internalization assay 
Molt-4  cells  were  incubated  with  various  con-
centrations of DLS and AMD for 30 min at 37ºC. Then, 
CXCL12 was added at a final concentration of 10nM 
and incubated for 90 min at 37ºC. Cells were washed 
with cold PBS and then FITC conjugated anti-human 
CXCR4 (12G5) antibody (BD Biosciences) added and 
incubated on ice for 30min. Again cells were washed 
with PBS and then fixed with 2% paraformaldehyde in 
PBS  before  being  analyzed  on  a  FACScan.  Data  is 
showed  as  a  graph  representing  mean  fluorescent 
intensity (MFI) of each treatment. 
Western blot analysis 
Activated T cells were treated with 20µM DLS or 
2µM  AMD  for  30min  at  37°C.  Then  CXCL12  was 
added at final concentration of 10nM and cells were 
washed with PBS and harvested and lysed in RIPA 
buffer supplemented with protease and phosphatase 
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) after 
1,  3  and  10minutes  of  addition  of  CXCL12.  Protein 
concentrations  of  cell  lysates  were  determined  by 
Bradford  assay.  Protein  lysates  (30g)  were  diluted 
with sample buffer and separated on 4-20% Tris HCl 
SDS-polyacrylamide gels (Biorad, Hercules, CA) and 
electrophoretically  transferred  to  nitrocellulose 
membranes  (Schleicher  &  Schuell).  The  blots  were 
then probed with mouse anti-phospho-ERK antibody 
(upper panel), stripped and again probed with rabbit 
anti-total-ERK antibody (lower panel) (Cell Signaling, 
Beverly, MA). Immune complexes were visualized by 
incubation with either an anti-rabbit or an anti-mouse 
HRP-conjugated  secondary  antibody  (Amersham, 
Piscataway, NJ). The immunoreactive band was visu-
alized  by  enhanced  chemiluminescence  (Per-
kin-Elmer). 
Chemotaxis Assay 
Fluorescence-based Transwell (Corning CoStar, 
Acton,  MA)  chemotaxis  assays  were  performed  to 
assess  cell  migration.  Primary  human  T  cells  were 
labeled with 5 μg/ml Calcein AM (Molecular Probes) 
in complete RPMI culture media (cRPMI) for 30 min 
at  37 °C  with  or  without  various  concentrations  of 
DLS and AMD. The cells were then resuspended in 
cRPMI to a concentration of 1 × 107 /ml and 100 ul of 
Calcein AM labeled cells (106 cells) were added into 
the Transwell filter (5 M pore size). cRPMI (0.6 ml) 
was added to the bottom wells of the 24-well plate 
with 10nM of CXCL12 with or without various con-
centrations of DLS and AMD. After 5 h incubation at 
37°C, chambers were removed and the plate was read 
on a Fluoroskan Ascent FL fluorescence plate reader 
(Thermo Labsystems, Franklin, MA) at λex = 485 nm, 
and λem = 590 nm. Results are expressed as migration 
index  calculated  by  subtracting  the  fluorescence  in-
tensity  of  the  “No  CXCL12”  negative  control  and 
comparing  the  values  to  the  fluorescence  intensity 
(relative  number)  of  cells  migrated  into  the  bottom 
chamber  in  the  “CXCL12  alone”  positive  control, 
which  is  normalized  to  a  value  of  1.  Fluorescence 
values were within the linear range of a standard di-
lution curve. 
HIV infection of T cells 
HIV1-IIIB was propagated in H9 cells and p24 
was  measured  in  sup  by  ELISA  (SAIC,  Frederick, 
USA).  PBMCs  were  activated  by  5g/ml  phytohe-
magglutinin  (PHA)  and  10units/ml  IL-2  for  three 
days.  On  day  three,  cells  were  washed  and  resus-
pended at one million per ml in complete RPMI cul-
ture (cRPMI) medium. Activated PBMCs were treated 
with various concentrations of DLS and AMD at 37°C 
for 30 minutes. Then, HIV1-IIIB was added to a final 
concentration of p24 of 10ng/ml. Cells were incubat-
ed at 37°C for three hours, washed to remove virus 
and resuspended at 500,000 cells/ml. Antagonist was 
added to the appropriate cell samples and cells were 
plated  as  triplicates  in  24  well  plates.  Supernatants 
were collected at day 3, 6 and 9 and p24 levels in su-
pernatants  were  measured  by  ELISA.  Data  graphs 
show % of p24 level over “virus only” controls at day 
6 and 9.  
Statistical Analysis 
Statistical analysis performed using student t test 
for differences in the means of each parameter exam-
ined.  For  several  of  the  studies  shown,  only  repre-
sentative data is shown as receptor expression on the 
T cell surface between donors or on T cell lines or the 
degree of calcium mobilization or cell migration var-
ied in degree from experiment to experiment; how-
ever, ultimately the findings were reproducible and at 
least three experiments were performed for all studies Int. J. Biol. Sci. 2012, 8 
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as well as a number of additional experiments noted 
as “data not shown”. 
Results 
DLS inhibits CXCL12 binding to CXCR4 
To determine if DLS blocks CXCL12 binding to 
CXCR4, we utilized a whole cell ligand binding assay 
with a biotinylated CXCL12, followed by binding of 
an avidin-fluorescein isothiocyanate (FITC) conjugate, 
and subsequent examination by using flow cytometric 
analysis. Upon DLS treatment, the percent maximal 
binding of CXCL12 in the GHOST-CXCR4 cells was 
reduced by 20 to 60% depending on the concentration 
of DLS being examined (Figure 2). These data suggest 
that  DLS  may  directly  block  ligand  binding  to  the 
CXCR4  receptor,  although,  microgram  quantities  of 
DLS was required for the observed inhibition while 
significantly less AMD3100 (between 500 ng-1 µg), a 
CXCR4 specific antagonist, was required to mediate 
similar inhibitory effects (data not shown). 
 
 
 
Figure 2. DLS blocks chemokine ligand binding to receptor-positive cells. 25µl of 4 million cells/ml T cells were incubated with or without 
different amount of DLS (1/4/16g) for 30 minutes at 37°C. 20 l of biotinylated-CXCL12 was added and cells were incubated for 1hr at 
4°C. After incubation, 20 µl of avidin-fluorescein was added to the tubes and incubated for 30 minutes at 4°C. The cells were subsequently 
washed with 1xRDF1 buffer, fixed with 2%PFA and analyzed on the FACScan. Histogram shows mean fluorescence intensity (MFI) for each 
treatment. Data shown is representative of at least four separate experiments.  Int. J. Biol. Sci. 2012, 8 
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Figure 3. D-Lys3-GHRP-6 inhibits CXCL12-induced intracellular calcium release from human T cells. T cells were loaded with Fura-2-AM dye, 
washed, and treated with different concentrations of DLS for 20 minutes. 1.5 ml cells were analyzed for Ca++ release after addition of 
CXCL12 (final concentration of 10nM) in a luminescence spectrometer. Each graph shows the 340nm/380nm excitation ratio at 509nm 
absorption. The data reveals that DLS partially inhibits CXCL12-induced Ca++ release (range of 20-60% inhibition). Data shown is 
representative of three separate experiments. 
 
 
D-Lys3-GHRP-6 inhibits CXCL12 induced in-
tracellular calcium release from human T cells. 
Ligation  of  seven  transmembrane  GPCRs  typi-
cally results in calcium mobilization from the intra-
cellular stores by generation of inositol triphosphate 
[1, 3]. CXCL12 binding to CXCR4 is known to elicit a 
potent release of calcium from intracellular sources. 
The direct effects of DLS on CXCL12- induced calcium 
mobilization  were  evaluated  on  primary  human  T 
cells labeled with Fura-2AM. CXCL12 at a final con-
centration  of  10nM  caused  a  significant  increase  in 
intracellular  calcium  and  this  CXCL12-induced  cal-
cium flux was markedly inhibited in a dose depend-
ent fashion by DLS (Figure 3).  
DLS inhibits CXCL12-induced T cell chemo-
taxis. 
We next determined the functional consequences 
of inhibition of CXCL12 binding to CXCR4 by DLS in 
a Transwell chamber migration assay. Primary human 
T cells, upon optimal CXCL12 treatment (10nM), ex-
hibited  robust  chemotaxis  and  pre-treatment  with 
DLS  led  to  marked  dose  dependent  inhibition  of 
CXCL12-induced  T  cell  migration  (Figure  4).  The 
CXCR4 specific antagonist, AMD, resulted in almost 
100% inhibition of CXCL12-induced migration, while 
DLS  treatment  resulted  in  a  20-60%  reduction  de-
pending on the DLS concentration being tested. The 
combination of AMD and DLS failed to have any ad-Int. J. Biol. Sci. 2012, 8 
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ditive  or  synergistic  effects  on  blocking 
CXCL12-mediated migration (data not shown). 
One  possible  mechanism  for  this  inhibition  of 
chemokine binding and signaling is the possible ef-
fects  of  DLS  on  CXCR4  internalization.  To  address 
this possibility, the Molt-4 T cell line was utilized, as it 
expresses high surface levels of CXCR4, and treated 
with different concentrations of DLS for 30 minutes 
after  which  the  cells  were  treated  with  or  without 
CXCL12 (10nM) for 90min to facilitate receptor inter-
nalization. The cells were then harvested, stained with 
anti-CXCR4-PE  antibody,  fixed  and  then  run  on  a 
FACScan. The results (Figure 5) demonstrate that DLS 
by itself failed to induce CXCR4 internalization and 
does not interfere with CXCL12-induced CXCR4 in-
ternalization. AMD alone or in combination with DLS 
also failed to mediate CXCR4 internalization alone or 
interfere  with  CXCL12-induced  CXCR4  internaliza-
tion (data not shown).  
DLS inhibits CXCL12-mediated signaling in 
activated T cells 
Activated  human  T  cells  were  pretreated  with 
either DLS (20M) for 30 minutes at 37°C. CXCL12 
was subsequently added and the cells were harvested 
and  examined  for  phosphorylated  ERK  at  the  indi-
cated times. These results (Figure 6) reveal that DLS 
very modestly blocks ERK activation in response to 
CXCL12 treatment in human T cells. Similar experi-
ments were performed using GHOST-CXCR4 cell line 
with  similar results (data not shown). Moreover, in 
separate control experiments, AMD3100 blocked ERK 
activation by 80% after CXCL12 treatment in activated 
human T cells at a 10-6M dose and combinations of 
AMD and DLS failed to mediate any additional inhi-
bition (data not shown).  
DLS decreases HIV-1 propagation in vitro in 
activated PBMCs cells.  
Given  the  ability  of  DLS  to  partially  abrogate 
chemokine binding and signaling, we sought to de-
termine if DLS could exhibit any inhibitory effects in 
HIV-1 infectivity in human PBMCs. Activated PBMCs 
were treated with DLS or the CXCR4 receptor antag-
onist,  AMD3100,  for  30  minutes  at  37°C.  HIV1-IIIB 
(CXCR4 tropic) was added to the cultures at 37°C for 3 
hours.  The  non-bound  virus  was  washed  off  the 
treated cells and the cells were cultured for 3, 6 or 9 
days to examine HIV-1 viral output by the infected 
cells. Supernatants were collected from each well at 
day 3, 6 and 9 and p24 levels were measured using 
ELISA assays. The results reveal that DLS inhibits X4 
tropic HIV-1 propagation in PBMCs (Figure 7).  
 
 
Figure 4. DLS inhibits CXCL12-induced chemotaxis. Activated T cells were loaded with Calcein AM dye, treated with different concen-
tration of DLS or the CXCR4 specific antagonist, AMD, for 30 minutes and were then examined for their ability to migrate in response to 
CXCL12 (10nM) in 24-well Transwell migration chambers. After 5 hours of incubation, the chambers were removed and the plates were 
read at 485/590 excitation/emission in a Cytofluor fluorimeter. The graph shows Migration Index or the ratio of migration of inhibitor plus 
CXCL12-induced cells over CXCL12-only induced cell migration. The results demonstrate that DLS inhibits CXCL12 induced activated 
T cell chemotaxis. Data shown are mean ±SEM and plotted as summary of three experiments, each done with three replicates. (* p<0.05) Int. J. Biol. Sci. 2012, 8 
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Figure 5. DLS does not influence CXCL12-induced CXCR4 internalization. Molt-4 cells were treated with different concentrations of DLS for 
30 minutes, then treated with or without CXCL12 (10nM final concentration) for 90min. The cells were then harvested in cold FACS 
buffer and stained with anti-CXCR4-PE (12G5) antibody for 45 minutes at 4°C. The stained cells were then washed and fixed with 2%PFA 
and samples acquired in FACScan. The graph shows average of two replicate’s mean fluorescence intensity (MFI) for each cell treatment. 
The  results  demonstrate  that  DLS  and  AMD  (data  not  shown)  do  not  internalize  CXCR4  by  itself  and  do  not  interfere  with 
CXCL12-induced CXCR4 internalization.  
 
Figure 6. DLS inhibits CXCL12-mediated signaling in activated T cells. Approximately 10 million activated T cells per 0.5ml were utilized per 
treatment. DLS (20M) was added to respective tubes and then incubated for 30 minutes at 37°C. CXCL12 (10nM) was subsequently 
added to the indicated tubes. The cells were then harvested in RIPA after washing with cold PBS at the indicated times. 30g of protein per 
sample were run on a 4-20% Bis-Tris gel, transferred and probed with mouse anti-phospho-ERK antibody (upper panel) stripped and again 
probed with rabbit anti-total ERK antibody (lower panel). The ratio of phospho vs. total ERK is shown below the top panel and the bottom 
graph shows levels of pERK as compared to only CXCL12control over various times following CXCL12 addition. Data shown here is of 
one experiment from total of three separate experiments.  Int. J. Biol. Sci. 2012, 8 
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Figure 7. DLS decreases HIV1-IIIB propagation in vitro in activated PBMCs. Activated PBMCs were washed and treated with DLS or AMD3100 
for 30 min at 37°C. 10ng (p24) of HIV1-IIIB (CXCR4 tropic) was added per 106 cells/ml, and then the cells were incubated at 37°C for 
3hrs. Cells were washed to remove virus and resuspended to a concentration of 500,000 cells/ml. Antagonists were added to appropriate 
tubes and cells were plated in triplicate in 24-well plates and incubated at 37°C. Supernatants were collected from each well at day 3 (data 
not shown), 6 and 9 and p24 levels were measured using ELISA. The graphs show % of p24 level over virus only controls at day 6 & 9. The 
results reveal that DLS inhibits X4 tropic HIV1-IIIB propagation in PBMCs. Data shown are mean ±SEM and plotted as summary of three 
experiments, each performed using different donors with three replicates in all cultures.(* p<0.05) 
 
 
Discussion 
Migration of immune cells to sites of inflamma-
tion is a multistep process mediated largely by inter-
actions  of  various  chemokines  to  their  G  protein 
linked seven transmembrane receptors [1, 3]. CXCR4 
is a chemokine receptor critical for cellular migration 
and is used in association with CD4 by human im-
munodeficiency virus (HIV) to enter its target cells. 
These co-receptors are important determinants of vi-
ral  tropism,  pathogenesis  and  virulence  and  are 
widely believed to be important drug targets to pre-
vent HIV infections [5]. Currently, AMD3100 a selec-
tive CXCR4 inhibitor has been successfully utilized to 
block CXCR4 mediated HIV viral entry [19] and also 
blocks  glioma  cell  invasion  [6]  and  metastasis  of 
breast  [20]  and  pancreatic  carcinoma  [21]  and  de-
creases allergy and collagen induced arthritis [22]. In 
addition  CXCR4  antagonists  have  recently  emerged 
as a potential candidate drugs to increase hematopoi-
etic stem cell (HSC) mobilization from bone marrow 
[23]. Typically, a high concentration of CXCL12, the 
natural CXCR4 ligand in bone marrow, is critical in 
retention of HSCs in bone marrow. The AMD3100’s 
Phase  II  and  planned  Phase  III  clinical  program  is 
designed  to  evaluate  the  ability  of  AMD3100  to  in-
crease  stem  cells  available  for  transplant  in  cancer 
patients.  
The  synthetic  peptidyl  compound, 
D-[Lys3]GHRP-6  (H-His-D-Trp-D-Lys-Trp-D-Phe- 
Lys-NH2), is currently believed to be a selective an-
tagonist of GHS-R. However, no studies exist on the 
potential  interaction  of  this  compound  with  other 
clinically  relevant  GPCRs  of  chemokine  family.  We 
have discovered that DLS can also modestly inhibit 
the binding and activity of CXCR4 receptor in human 
T  cells.  While  DLS  may  be  blocking  or  hindering 
CXCL12  binding  to  the  ligand  binding  site  of  the 
CXCR4 surface receptor, it is also feasible that DLS 
may  also  act  indirectly  by  activating  intracellular 
signaling and/or phosphorylation events that alters 
CXCR4  conformation  and  thus  reducing  its  affinity 
for CXCL12. We have previously demonstrated that 
the  conformation  of  CXCR4  can  influence  ligand 
binding  in  T  cells  as  well  as  HIV-1  infectivity  [18]. 
Given the modest inhibition of calcium mobilization 
and ERK activation, DLS appears only to be a partial 
receptor antagonist to CXCR4 and may be blocking 
ligand  binding  by  non-traditional  mechanisms. 
Nonetheless, these data do support that DLS may not 
be  the  exclusive  GHS-R1a  antagonist  that  has  been 
reported in the literature. 
DLS  has  also  been  utilized  experimentally  in 
rodent models without any adverse side effects and 
repeated  administration  have  been  found  to  reduce 
body weight in obese mice and improve their glyce-Int. J. Biol. Sci. 2012, 8 
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mic  control  and  insulin  resistance,  all  presumably 
through it’s blocking of acylated ghrelin binding to 
the GHS-R [24]. Furthermore, DLS reduced the size of 
abdominal fat pads without affecting the muscle mass 
in these mice. There is accumulating clinical evidence 
linking  currently  used  HIV  inhibitors  to  the  patho-
genesis  of  insulin  resistance,  dyslipidemia,  lipo-
dystrophy and atherosclerosis in AIDS patients [25]. 
Thus,  DLS  along  with  its  potential  HIV  inhibitory 
properties  may  attenuate,  alone  or  in  combination 
with other therapeutics, the metabolic effects associ-
ated with HAART therapy in AIDS patients. Moreo-
ver, DLS does not affect food intake in the fed state 
when circulating ghrelin levels are low, thus permit-
ting its potential use post-prandially. Our findings of 
DLS as a modest CXCR4 inhibitor thus suggests that 
further development of the DLS peptide may lead to 
effective classes  of anti-cancer and anti-HIV agents. 
However, in its current form and potency, our data 
with  DLS  does  not  suggest  a  clinical  role  for  this 
compound.  
Therapy  for  HIV-1  infected  subjects  includes 
reverse  transcriptase  and  protease  inhibitors.  These 
inhibitors  have  achieved  sustained  suppression  of 
viral  replication  in  HIV-1-infected  individuals,  alt-
hough the HIV-1 virus may develop resistance to one 
or more agents. These inhibitors are costly and require 
long-term  use.  Despite  the  efficacy  of  these  agents, 
there is still dire need to discover new anti-HIV agents 
to inhibit viral infectivity. CXCR4 and CCR5 are the 
major co-receptors for HIV-1 entry into the CD4 posi-
tive cells. Several of the SNPs and specific deletions in 
CXCR4 and CCR5 genes have been shown to result in 
a resistance to or slower progression of HIV-1 infec-
tion without any substantial immune (functional) de-
fect in humans. Thus, it would appear that chemokine 
receptors,  more  specifically  CXCR4  and  CCR5,  are 
attractive targets to block HIV-1 binding, fusion and 
infectivity. AMD3100 has been found to be a potent 
CXCR4 [15] blocking agent. However, these antago-
nists have had little success in clinical trials. Recent 
work by Won-Tak Choi and colleagues [26] have re-
vealed  that  D-amino  acid  (aa)  modified  CXCL12 
demonstrates  some  specific  gp120  blocking  activity 
compared to an unmodified peptide. As we are using 
DLS in these studies (a six amino acid peptide that is 
comprised  of  three  D-aa),  we  hypothesize  that  the 
D-aa  in  DLS  may  be  contributing  to  the  decreased 
propagation of HIV-1 in vitro through its interaction 
with  chemokine  receptors.  We  are  currently  testing 
new sets of peptides with additional D-aa as well as 
D-aa-free peptides to assess the potential role of the D 
forms in our observed activities.  
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